Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow and rapid progression forms could provide valuable information for improved early detection and management. Unfortunately, this represents a complex problem due to the heterogeneous nature of humans in regards to demographic characteristics, genetics, diet, environmental exposures and health behaviors. In this pilot study, we employed high resolution mass spectrometry-based metabolic profiling to investigate the metabolic signatures of slow versus rapidly progressing PD present in human serum. Archival serum samples from PD patients obtained within 3 years of disease onset were analyzed via dual chromatography-high resolution mass spectromet...
Abstract Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challen...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
International audienceBackgroundCare management of Parkinson's disease (PD) patients currently remai...
<div><p>Progression of Parkinson’s disease (PD) is highly variable, indicating that differences betw...
Progression of Parkinson's disease (PD) is highly variable, indicating that differences between slow...
Introduction: About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understa...
Parkinson ’ s disease (PD) is a multifactorial neurodegenerative disorder in which environmental (li...
Differentiating between Parkinson’s disease (PD) and the atypical Parkinsonian disorders of multiple...
Differentiating between Parkinson’s disease (PD) and the atypical Parkinsonian disorders of multiple...
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the cent...
Parkinson’s disease (PD) shows high heterogeneity with regard to the underlying molecular pathogenes...
Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring dopamine metabol...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Abstract Background Untargeted high-resolution metabolomic profiling provides simultaneous measureme...
Abstract Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challen...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
International audienceBackgroundCare management of Parkinson's disease (PD) patients currently remai...
<div><p>Progression of Parkinson’s disease (PD) is highly variable, indicating that differences betw...
Progression of Parkinson's disease (PD) is highly variable, indicating that differences between slow...
Introduction: About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understa...
Parkinson ’ s disease (PD) is a multifactorial neurodegenerative disorder in which environmental (li...
Differentiating between Parkinson’s disease (PD) and the atypical Parkinsonian disorders of multiple...
Differentiating between Parkinson’s disease (PD) and the atypical Parkinsonian disorders of multiple...
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the cent...
Parkinson’s disease (PD) shows high heterogeneity with regard to the underlying molecular pathogenes...
Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring dopamine metabol...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Abstract Background Untargeted high-resolution metabolomic profiling provides simultaneous measureme...
Abstract Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challen...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
International audienceBackgroundCare management of Parkinson's disease (PD) patients currently remai...